CervoMed to Participate in the Emerging Growth Conference
Wednesday, July 17, 2024 1 min read
Key Takeaway: CervoMed Inc. will present virtually at the Emerging Growth Conference on July 18, 2024. The company focuses on developing treatments for age-related neurologic disorders, particularly through its investigational drug, neflamapimod. This small molecule aims to address synaptic dysfunction in neurodegenerative diseases, including dementia with Lewy bodies (DLB). Currently, neflamapimod is under investigation in a Phase 2b study.
Market Sentiment Analysis
POSITIVE FACTORS
CervoMed is actively participating in the Emerging Growth Conference, highlighting its engagement with investors.
The company's investigational drug, neflamapimod, shows promise in treating age-related neurologic disorders.
Neflamapimod is currently in a Phase 2b study, indicating progress in clinical development.
Full Press Release Details
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company’s Management will present virtually at the Emerging Growth Conference.
Presentation Details
Format: Corporate presentation
Date: Thursday, July 18, 2024
Webcast Link: click here
The webcast of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
CervoMed Inc. (the “Company”) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.